Non-Factor Replacement Therapy in Hemophilia

CE / CME

Innovations in Hemophilia Treatment: Current and Emerging Non-Factor Therapies

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 21, 2025

Expiration: September 20, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 9-year-old boy with severe hemophilia A and high-titer inhibitors has experienced multiple joint bleeds despite prophylaxis with a bypassing agent. His parents seek a subcutaneous treatment to reduce bleeding risk and treatment burden. Given his clinical history, which therapy would be the most appropriate option?

2.

A 35-year-old man with hemophilia B and high-titer inhibitors has been struggling with frequent breakthrough bleeds despite using a bypassing agent for prophylaxis. He has poor venous access and struggles with adherence to intravenous treatments. Which therapy would be most appropriate for him?

3.

Which of the following strategies should you consider to reduce thrombosis risk with concizumab while maintaining efficacy?